Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

@article{Castro2015ReslizumabFI,
  title={Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.},
  author={Mario Castro and James G. Zangrilli and Michael E. Wechsler and Eric D Bateman and Guy G Brusselle and Philip G. Bardin and Kevin R. Murphy and Jorge Fernando Maspero and Christopher O'brien and Stephanie Korn},
  journal={The Lancet. Respiratory medicine},
  year={2015},
  volume={3 5},
  pages={355-66}
}
BACKGROUND Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations. Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death. We aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, moderate-to-severe asthma. METHODS We did two duplicate, multicentre, double-blind, parallel-group, randomised, placebo-controlled phase 3 trials. Both trials enrolled… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
124 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 124 extracted citations

Similar Papers

Loading similar papers…